Alpha 2.0
Login Register
» Authors » Yingnian Chen

Yingnian Chen

Explore the profile of Yingnian Chen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 61
Followers 0
Related Specialties
Hematology
Oncology
Cell Biology
Top 10 Co-Authors
Sanbin Wang
Yu Li
Lin Liu
Zhongtao Yuan
Shiqi Li
Le Luo
Xiaoping Li
Yancheng Dong
Dingsong Zhang
Lvzhe Chen
Published In
EJHaem
Clin Cancer Res
Leukemia
Cell Transplant
Cell Stem Cell
Affiliations
Soon will be listed here.
Recent Articles
1.
The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation
Li X, Li Y, Zhang D, Hu X, Liu L, Yuan Z, et al.
Cell Transplant . 2025 Jan; 34:9636897241303292. PMID: 39874071
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to...
2.
Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study
Jiang J, Li X, Wu D, Lu Q, Miao K, Wang H, et al.
EJHaem . 2024 Aug; 5(4):757-767. PMID: 39157627
Relapse remains the main cause of treatment failure in patients with myeloid malignancies even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We observed a particularly low incidence of relapse in...
3.
Stable engraftment, as well as graft versus host disease-free and relapse-free survival brought by the combination of CD7 targeted universal chimeric antigen receptor-T, and donor hemopoietic stem cells: Indication of a case report
Li S, Yuan Z, Liu L, Li Y, Luo L, Peng L, et al.
EJHaem . 2024 Jun; 5(3):584-588. PMID: 38895056
CD7 targeted CAR-T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo-HSCT. Here...
4.
Modified lentiviral globin gene therapy for pediatric β/β transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial
Li S, Ling S, Wang D, Wang X, Hao F, Yin L, et al.
Cell Stem Cell . 2024 May; 31(7):961-973.e8. PMID: 38759653
β/β thalassemia is the most severe type of transfusion-dependent β-thalassemia (TDT) and is still a challenge facing lentiviral gene therapy. Here, we report the interim analysis of a single-center, single-arm...
5.
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, et al.
Leukemia . 2023 Sep; 37(11):2176-2186. PMID: 37700087
T-cell acute lymphoblastic leukemia (T-ALL) represents an area of highly unmet medical needs. Once relapsed, patients have limited treatment options and poor prognosis. T-ALL antigens such as CD7 is extensively...
6.
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management
Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, et al.
Clin Cancer Res . 2020 Nov; 27(5):1242-1246. PMID: 33234511
Purpose: Although chimeric antigen receptor T-cell (CAR-T) therapy development for B-cell malignancies has made significant progress in the last decade, broadening the success to treating T-cell acute lymphoblastic leukemia (T-ALL)...